INTRODUCTION
• Multiple myeloma (MM) is the second most prevalent blood cancer in Canada [1] .
• In patients who have undergone autologous stem cell transplant (ASCT) treatment, maintenance therapy (MT) post-transplant has been shown to substantially prolong progression-free survival.
• Lenalidomide and bortezomib may be used as post-transplant MTs in ASCT eligible patients.
• However there is a lack of published data on the relative costs of the two regimens when used in MT for patients who have undergone ASCT.
OBJECTIVES
• We sought to quantify and compare total therapy costs for the two MTs, bortezomib and lenalidomide, in MM patients who have undergone ASCT.
METHODS

RESULTS
METHODS
Analysis Overview
• Analyses were conducted to estimate the annual incremental cost differences per patient for bortezomib versus lenalidomide MT.
• The approach taken to conduct this analysis is presented in Figure 1 . 
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DISCUSSION
• The results of this analysis suggest that when comparing MTs, bortezomib is much less costly than lenalidomide.
• There are a number of limitations associated with this analysis, however wherever possible measures were taken to use conservative assumptions in the analysis.
-There are limitations associated with the studies that were used to provide a basis for the parameter estimates such as the following:
▪ There were differences in the treatment prior to MT (e.g., heavier consolidation of multiple ASCTs in the trial reported by Attal et al in 2012) that may have contributed to higher discontinuation rates in the maintenance phase and possibly even higher rates of AEs. However it is unclear to what extent these would be impacted and therefore the parameters were tested in sensitivity analyses.
▪ Inconsistent reporting of outcomes or limited reporting of outcomes made some comparisons difficult to conduct and were therefore not evaluated in this analysis (e.g., transfusion requirements) [2, 3, 4] .
-There is uncertainty associated with the AE and SPM rates, as comparative data were not available in head-tohead RCTs, however they were included to ensure additional costs were accounted for, and their impact on the results were tested in one-way sensitivity analyses and shown to not be drivers of the cost differences.
-A naive indirect comparison of the single arms of the studies was conducted given the there were no common comparators by which a more formal ITC could be conducted, however without doing so, this analysis would not be possible.
• In the absence of clear comparative clinical efficacy, the choice of MT may be influenced by patient characteristics as well as patient and physician preference.
-Economic impact of treatment options may also be considered, however further research is required.
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Parameters
Analyses
• The base case analysis included drug costs and administration costs associated with each MT.
• Additional analyses were conducted to also consider the economic impact of: 1) experiencing adverse events (AEs).
2) developing treatment associated second primary malignancies (SPMs).
Inputs and Assumptions
• Table 1 outlines key parameter inputs.
• Inputs and assumptions were based on representative trials for respective treatments [2, 3, 4] as well as Canadian clinical expert opinion.
-For bortezomib, the HOVON-65/GMMG-HD4 trial was considered the most representative. ▪ The trial evaluated IV bortezomib while in practice SC administration may be more likely. Given differences in the safety profile of IV compared with SC administration it was considered conservative to use the values reported in the trial given they would not underestimate the costs associated with bortezomib. -The estimated bortezomib administration costs were based on the regimen on the Cancer Care Ontario recommendations for bortezomib. ▪ Oncology nurse (41.7 minutes) [5, 6] ▪ Pharmacist workload (9.8 minutes) [5, 7] • The mark-up and dispensing fees applied to the acquisition costs of drugs in Canada are variable; it may depend on many factors including provincial regulation differences.
-Pharmacy fees were not added to the acquisition cost of lenalidomide, as it was assumed that lenalidomide may be obtained from a hospital pharmacy that would not be subjected to a pharmacy mark-up or dispensing fee. AEs • AEs were included if they were commonly reported in clinical trials evaluating bortezomib [4] or lenalidomide [2, 3] as MT for patient eligible for ASCT or if they were considered important by Canadian clinicians. • The probability of experiencing an AE was estimated based on the AE rates reported in the above trials.
-For lenalidomide, the weighted average based on the sample size of each trial was taken from McCarthy 2012 and Attal 2012.
• AEs were broadly classified as follows:
-Hematological events (i.e., neutropenia, thrombocytopenia, anemia, or febrile neutropenia) -GI symptoms (i.e., nausea/vomiting, diarrhea) -Other non-hematological events (i.e., pain/peripheral neuropathy, infections, venous thrombolic events/ pulmonary embolisms, rash, and fatigue, and cardiac events) • Management costs for each AE were estimated based on resource use associated with treatment considering the weighted probability of requiring hospitalization versus outpatient care.
-Hospitalization costs were obtained from the Ontario Case Costing Initiative [8] .
-Outpatient management costs included drug treatment, laboratory tests, nurse care, oncologist visits, and the duration of treatment.
• Dose reductions as a result of AEs were assumed to occur and therefore a relative dose intensity (RDI) of 0.8 was applied to both MTs, which is consistent with the 0.83 RDI reported by Attal et al. in 2012 (data was unavailable for the other trials). SPMs • The probability of developing a SPM was calculated for a one year time period.
-For lenalidomide, the proportion of patients and the median follow-up time reported in the trials [2, 3] were used in the calculations. -For bortezomib, the HOVON-65/GMMG-HD4 publication did not report SPMs [4] , however extended follow-up data was presented in an abstract by Sonneveld et al. in 2013 which reported a proportion of patients who developed SPMs at 5 years and was therefore used with the reported median follow-up time in the calculations. The equations used were as follows (where p is the probability, r is the rate, t is the unit of time) [15] :
Sensitivity Analyses
• One-way sensitivity analyses were conducted to test the impact of parameters on the net incremental cost difference between MTs by varying key cost inputs by ±20%.
• In addition, sensitivity analyses were run with an RDI of 1.0, treatment for a two year time horizon, or a 10% pharmacy mark-up and $8.53 dispensing fee every 90 days included in the acquisition cost of lenalidomide [14] .
• The total annual costs of treatment per patient were $32,560 and $131,765 for bortezomib and lenalidomide, respectively (Table 2, Figure 2 ).
• Cost savings were associated with bortezomib MT when compared with lenalidomide MT in all three analyses (Table 2, Figure 2 ).
• The incremental differences were robust to changes in inputs and assumptions (Figure 3 ).
-Differences in overall costs between MTs were driven primarily by drug costs, and to a much less extent, administration fees.
-AEs and SPMs had little impact on the results.
• When the RDI was considered 1.0, when the time horizon was increased to two years, or when pharmacy mark-up and dispensing fees were considered in the acquisition cost of lenalidomide, cost savings associated with bortezomib increased when compared to lenalidomide (Table 3 ).
• The cost to treat SPMs reflects an average cost per course of oncology treatment per patient, inflated to 2013 Canadian dollars [9] . *An RDI of 0.8 was applied to account for dose adjustments due to AEs which resulted in cost reductions. 
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